Zavante's Zolyd meets in pivotal cUTI study

Zavante Therapeutics Inc. (San Diego, Calif.) said Zolyd fosfomycin (ZTI-01) met the primary endpoint in the Phase II/III ZEUS trial

Read the full 206 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE